Clinical trial · Interventional
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients With Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy
NCT01505530CI-TRIAL-00040670completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This phase 2 study is a multicenter, randomized, double-blind, placebo-controlled trial in participants with locally advanced/inoperable or metastatic pancreatic cancer, and will investigate 2 different doses of LY2495655 in combination with standard of care chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LY2495655 | Drug | — | UNRESOLVED |
| Placebo | Drug | — | UNRESOLVED |
| Standard of Care Chemotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- 300 mg LY2495655 + chemotherapy
- description
- 300 mg LY2495655 intravenous (IV) in combination with standard of care chemotherapy (investigator's choice)
- interventionNames
- Drug: LY2495655
- Drug: Standard of Care Chemotherapy
- type
- EXPERIMENTAL
- label
- 100 mg LY2495655 + chemotherapy
- description
- 100 mg LY2495655 intravenous (IV) in combination with standard of care chemotherapy (investigator's choice)
- interventionNames
- Drug: LY2495655
- Drug: Standard of Care Chemotherapy
- type
- PLACEBO_COMPARATOR
- label
- Placebo + chemotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion: * Unresectable or metastatic pancreas cancer; participants with previous radical surgery for pancreas cancer are eligible after progression is documented * Participants may have received previous adjuvant treatment with gemcitabine with or without radiotherapy for pancreas cancer * ECOG (Eastern Cooperative Oncology Group) Performance status ≤ 2 * Adequate organ function * Have an estimated life expectancy of at least 12 weeks and in the judgment of the investigator, will be able to complete at least 2 cycles of treatment * Ability to perform the indicated functional performance measures at baseline Exclusion: * Prior systemic therapy for unresectable/metastatic pancreas cancer * Any medical or psychiatric condition, orthopedic or neuromuscular conditions that could limit participation or confound study results * Currently taking medications that are considered both muscle building and performance enhancing (for example, androgen therapies, or anabolic steroids)
References
Publications (0)
Data not yet available
No reference posted for this study.